Marco Meglio

Steve Hughes, MD, chief medical officer at Avidity, provided perspective on recently announced positive phase 1/2 and OLE data evaluating AOC 1001, an investigational antisense oligonucleotide, in patients with myotonic dystrophy type 1.

Patients with multiple sclerosis (MS) showed cognitive improvements with frontal theta-transcranial alternating current stimulation (tACS), suggesting its potential as a tolerable and beneficial intervention.

The phase 2 EMBOLD study on ATA188, an allogenic T-cell immunotherapy for non-active progressive multiple sclerosis, did not meet its primary endpoint of confirmed disability improvement after 12 months of treatment.

A retrospective study on veterans using lamotrigine found no clear association between the drug and cardiac conduction abnormalities, prompting the need for further research.

The reported neurofilament light elevation preceding confirmed disability worsening events highlighted the value of NfL as an early biomarker of disability worsening and points to the existence of different windows of dynamic central nervous system pathology.

Over a year’s worth of treatment, investigators observed consistent and persistent efficacy in pain relief, pain freedom, functional disability relief, and functional disability freedom.

The chief medical officer of NeuroTherapia provided insight on promising phase 1b data assessing NTRX-07, a CBR2-targeting agent in development for patients with early-stage Alzheimer disease.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Barry J. Byrne, MD, PhD. [LISTEN TIME: 10 minutes]

Preliminary data from a phase 1 study suggest that ALKS 2680, an investigational orexin 2 receptor agonist, is safe and improves sleep latency in narcolepsy patients, leading to plans for a phase 2 study.

Modius Sleep is designed to send a safe electrical pulse into the vestibular nerve, influencing the areas of the hypothalamus and brain stem that control circadian rhythm and sleep patterns.

A study on patients with Friedreich ataxia showed that cervical spinal cord cross-sectional area is a potential biomarker for disease progression, particularly at C1 level.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Alfonso Fasano, MD, PhD. [WATCH TIME: 25 minutes]

A retrospective study presented at the 2023 AANEM meeting revealed that social determinants of health are linked to poorer treatment outcomes in myasthenia gravis patients, emphasizing the need for identifying and supporting at-risk individuals.

In the phase 3 TOLEDO trial, treatment with SPN-830 resulted in significantly greater OFF time for patients with Parkinson disease in comparison with those on placebo.

Elevated creatine kinase levels were not found to be a prognostic factor for the development of PASC in encephalopathic COVID-19 patients, according to a retrospective chart review analysis.

Vutrisiran and patisiran treatment led to noticeable reductions in neurofilament light, indicating a potential biomarker of treatment response in hATTR amyloidosis patients.

The phase 3 PROPEL study demonstrated the long-term effectiveness of cipaglucosidase alfa/miglustat in late-onset Pompe disease, with improved 6-minute walk distance and lung function.

latozinemab treatment for C9orf72-associated frontotemporal dementia showed no significant impact on disease progression, although the treatment was generally safe and well-tolerated.

David Greeley, MD, chief medical officer at AriBio and study author, provided commentary on the mechanism of action of AR1001, its promising effect on ptau181, and the next steps in its development.

Over a 52-week treatment period, SRP-9001 demonstrated robust evidence for a clinically meaningful benefit across several prespecified functional secondary end points in comparison with placebo.

In a sample of more than 750 patients with migraine, clinician specialty had no impact on preventive prescription, with small differences observed in the choice of tricyclic antidepressants.

Results showed that the relative reduction (RR) in CDR-SB at end-of-study was moderately correlated with difference between treated and placebo in Centiloid change.

START will assess the potential of delaying non–vitamin K oral anticoagulant therapy following stroke related to atrial fibrillation in a large cohort of patients

A group of sleep experts discuss the importance of timely and accurate diagnosis, recent approvals, and available treatment options for managing a chronic disorder and its symptoms.

At 40 weeks, there were no observed cases of ARIA-edema, and new microhemorrhages occurred predominantly in patients with pre-existing conditions.

ACU193 treatment reduced amyloid plaques in early Alzheimer disease patients, suggesting AßOs as a viable target, with safety data and ARIA analysis presented at CTAD 2023.

The use of focused ultrasound-mediated blood-brain barrier opening has the potential to advance neurotherapeutics in the treatment of Alzheimer disease and other progreesive neurological disorder impacted by that barrier.

New subcutaneous lecanemab considered more effective than IV for amyloid plaque removal in Alzheimer disease; FDA application planned by March 2024.

Findings from the phase 2a AscenD-LB, a study of neflamapimod in patients with mild-to-moderate Alzheimer disease, served as supportive data to guide the phase 2b study.

Over the 18-month treatment period, investigators observed no amyloid-related imaging abnormalities along with continued slowing of disease progression in patients with mild to moderate Alzheimer disease.